IDEXX Laboratories Company Insiders
| IDXX Stock | USD 477.79 0.45 0.09% |
IDEXX Laboratories' insiders are aggressively selling. The analysis of insiders' sentiment of trading IDEXX Laboratories stock suggests that vertually all insiders are panicking at this time. IDEXX Laboratories employs about 11 K people. The company is managed by 33 executives with a total tenure of roughly 276 years, averaging almost 8.0 years of service per executive, having 333.33 employees per reported executive.
| Jonathan Ayers Chairman Chairman, CEO and Pres |
| Kathy Turner President Corporate Vice President |
IDEXX Laboratories' Insider Buying Vs Selling
0
Selling | Buying |
Latest Trades
| 2024-02-08 | George Fennell | Disposed 8198 @ 573.87 | View | ||
| 2024-02-07 | Jonathan Jay Mazelsky | Disposed 12000 @ 572.61 | View | ||
| 2024-01-22 | Tommy Tuberville | Disposed @ 531.43 | |||
| 2023-12-07 | James F Polewaczyk | Disposed 11636 @ 521.79 | View | ||
| 2023-12-04 | Jonathan Jay Mazelsky | Disposed 7128 @ 513.05 | View | ||
| 2023-08-31 | Jonathan Jay Mazelsky | Disposed 13424 @ 512.01 | View | ||
| 2023-08-29 | James F Polewaczyk | Disposed 22909 @ 510.56 | View | ||
| 2023-08-03 | Michael Lane | Disposed 16027 @ 510 | View | ||
| 2023-05-18 | Jonathan W Ayers | Disposed 10000 @ 489.23 | View | ||
| 2023-05-05 | Michael Lane | Disposed 1000 @ 484 | View | ||
| 2023-05-04 | Sophie V Vandebroek | Disposed 2187 @ 469.02 | View |
Monitoring IDEXX Laboratories' insider sentiment can offer insights into its future performance, as insiders often have access to more information about their company's operations, financial health, and upcoming initiatives than the general public. However, it's essential to note that insider trading is regulated by securities laws, and insiders are required to disclose their trades publicly to ensure transparency and prevent unfair advantages based on non-public information.
IDEXX |
IDEXX Laboratories' Workforce Through the Years
Please note that employee historical analysis has become an increasingly important factor for investors assessing the risk associated with IDEXX Laboratories' future performance. Based on our forecasts, it is anticipated that IDEXX will maintain a workforce of slightly above 11000 employees by May 2024.IDEXX Laboratories' latest congressional trading
Congressional trading in companies like IDEXX Laboratories, is subject to rigorous scrutiny to prevent conflicts of interest and insider trading. This is governed by multiple SEC regulations which were established to foster transparency and deter members of Congress from leveraging non-public information for personal gain. This oversight helps maintain public trust and ensures that investments in IDEXX Laboratories by those in governmental positions are based on the same information available to the general public.
| 2024-01-22 | Senator Thomas H Tuberville | Acquired Under $15K | Verify | ||
| 2023-04-03 | Senator Tommy Tuberville | Acquired Under $15K | Verify | ||
| 2020-10-09 | Representative Gilbert Cisneros | Disposed Under $15K | Verify |
IDEXX Laboratories Management Team Effectiveness
The company has return on total asset (ROA) of 0.2283 % which means that it generated a profit of $0.2283 on every $100 spent on assets. This is way below average. Similarly, it shows a return on stockholder's equity (ROE) of 0.8074 %, meaning that it created $0.8074 on every $100 dollars invested by stockholders. IDEXX Laboratories' management efficiency ratios could be used to measure how well IDEXX Laboratories manages its routine affairs as well as how well it operates its assets and liabilities. At this time, IDEXX Laboratories' Return On Tangible Assets are fairly stable compared to the past year. Return On Assets is likely to rise to 0.27 in 2024, whereas Return On Capital Employed is likely to drop 0.26 in 2024. At this time, IDEXX Laboratories' Return On Assets are fairly stable compared to the past year.Common Stock Shares Outstanding is likely to rise to about 94.9 M in 2024. Net Income Applicable To Common Shares is likely to rise to about 820 M in 2024
IDEXX Laboratories Workforce Comparison
IDEXX Laboratories is rated below average in number of employees category among related companies. The total workforce of Health Care industry is currently estimated at about 218,858. IDEXX Laboratories holds roughly 11,000 in number of employees claiming about 5% of equities under Health Care industry.
IDEXX Laboratories Profit Margins
The company has Profit Margin (PM) of 0.23 %, which maeans that even a very small decline in it revenue will erase profits resulting in a net loss. This is way below average. Similarly, it shows Operating Margin (OM) of 0.27 %, which suggests for every 100 dollars of sales, it generated a net operating income of $0.27.| Current Value | Last Year | Change From Last Year | 10 Year Trend | ||||||
|---|---|---|---|---|---|---|---|---|---|
| Gross Profit Margin | 0.61 | 0.5982 |
|
| |||||
| Net Profit Margin | 0.24 | 0.2308 |
|
| |||||
| Operating Profit Margin | 0.31 | 0.2997 |
|
| |||||
| Pretax Profit Margin | 0.3 | 0.2899 |
|
| |||||
| Return On Assets | 0.27 | 0.2592 |
|
|
IDEXX Laboratories Insider Trading History
Some recent studies suggest that insider trading raises the cost of capital for securities issuers and decreases overall economic growth. Trading by specific IDEXX Laboratories insiders, such as employees or executives, is commonly permitted as long as it does not rely on IDEXX Laboratories' material information that is not in the public domain. Local jurisdictions usually require such trading to be reported in order to monitor insider transactions. In many U.S. states, trading conducted by corporate officers, key employees, directors, or significant shareholders must be reported to the regulator or publicly disclosed, usually within a few business days of the trade. In these cases, IDEXX Laboratories insiders must file a Form 4 with the U.S. Securities and Exchange Commission (SEC) when buying or selling shares of their own companies.
| Buy/Sell Ratio | # Purchases Trades | # Sales Trades | Total Shares Purchased | Total Shares Sold | |
|---|---|---|---|---|---|
| 2024-03-01 | 0.6642 | 89 | 134 | 142,692 | 233,465 |
| 2023-12-01 | 0.4375 | 7 | 16 | 26,807 | 54,826 |
| 2023-09-01 | 0.5517 | 16 | 29 | 195,491 | 250,420 |
| 2023-06-01 | 0.8095 | 34 | 42 | 24,953 | 62,208 |
| 2023-03-01 | 1.1833 | 71 | 60 | 112,250 | 56,054 |
| 2022-12-01 | 0.2857 | 8 | 28 | 64,941 | 114,086 |
| 2022-09-01 | 0.7143 | 5 | 7 | 450,612 | 455,852 |
| 2022-06-01 | 3.375 | 27 | 8 | 16,783 | 2,610 |
| 2022-03-01 | 1.3333 | 76 | 57 | 109,530 | 29,526 |
| 2021-12-01 | 0.3214 | 9 | 28 | 49,092 | 99,146 |
| 2021-09-01 | 0.3582 | 24 | 67 | 36,716 | 78,413 |
| 2021-06-01 | 0.7436 | 29 | 39 | 48,528 | 109,096 |
| 2021-03-01 | 1.012 | 84 | 83 | 172,760 | 139,542 |
| 2020-12-01 | 0.1008 | 12 | 119 | 61,167 | 260,816 |
| 2020-09-01 | 0.3793 | 22 | 58 | 207,426 | 443,703 |
| 2020-06-01 | 0.9189 | 34 | 37 | 128,990 | 292,419 |
| 2020-03-01 | 0.4812 | 64 | 133 | 191,946 | 320,807 |
| 2019-12-01 | 0.5455 | 12 | 22 | 107,422 | 248,815 |
| 2019-09-01 | 0.75 | 27 | 36 | 112,012 | 159,916 |
| 2019-06-01 | 1.1053 | 21 | 19 | 57,765 | 95,599 |
| 2019-03-01 | 0.825 | 66 | 80 | 248,124 | 182,324 |
| 2018-12-01 | 1.0 | 6 | 6 | 8,790 | 43,728 |
| 2018-09-01 | 0.7143 | 25 | 35 | 173,448 | 244,035 |
| 2018-06-01 | 0.6452 | 20 | 31 | 18,847 | 139,394 |
| 2018-03-01 | 0.7778 | 49 | 63 | 283,378 | 267,779 |
| 2017-12-01 | 0.2121 | 7 | 33 | 49,725 | 231,932 |
| 2017-09-01 | 0.6897 | 20 | 29 | 128,414 | 236,196 |
| 2017-06-01 | 1.3333 | 24 | 18 | 135,117 | 213,874 |
| 2017-03-01 | 1.0238 | 43 | 42 | 315,068 | 228,188 |
| 2016-12-01 | 0.4 | 12 | 30 | 86,515 | 259,765 |
| 2016-09-01 | 0.5789 | 11 | 19 | 180,213 | 325,435 |
| 2016-06-01 | 4.2 | 21 | 5 | 70,724 | 24,851 |
| 2016-03-01 | 1.25 | 50 | 40 | 473,799 | 72,298 |
| 2015-12-01 | 0.7273 | 8 | 11 | 39,442 | 49,642 |
| 2015-09-01 | 0.7647 | 13 | 17 | 58,579 | 88,023 |
| 2015-06-01 | 2.4444 | 22 | 9 | 57,016 | 31,676 |
| 2015-03-01 | 0.8852 | 54 | 61 | 286,385 | 245,302 |
| 2014-12-01 | 0.5652 | 13 | 23 | 90,433 | 163,636 |
| 2014-09-01 | 1.4 | 14 | 10 | 48,740 | 43,162 |
| 2014-06-01 | 2.4444 | 22 | 9 | 34,909 | 14,430 |
| 2014-03-01 | 1.2162 | 45 | 37 | 255,611 | 202,219 |
| 2013-12-01 | 0.8421 | 32 | 38 | 362,910 | 530,970 |
| 2013-09-01 | 0.8571 | 6 | 7 | 25,442 | 40,134 |
| 2013-06-01 | 1.5333 | 23 | 15 | 72,806 | 40,328 |
| 2013-03-01 | 0.9714 | 102 | 105 | 429,536 | 572,563 |
| 2012-12-01 | 0.42 | 21 | 50 | 177,995 | 394,152 |
| 2012-09-01 | 0.6 | 27 | 45 | 141,810 | 239,572 |
| 2012-06-01 | 1.1818 | 26 | 22 | 82,212 | 111,342 |
| 2012-03-01 | 1.4615 | 76 | 52 | 238,745 | 99,586 |
| 2011-12-01 | 0.4091 | 9 | 22 | 92,899 | 154,958 |
| 2011-09-01 | 0.6316 | 12 | 19 | 115,509 | 202,241 |
| 2011-06-01 | 0.9394 | 31 | 33 | 225,109 | 289,654 |
| 2011-03-01 | 1.3118 | 122 | 93 | 667,530 | 472,107 |
| 2010-12-01 | 0.75 | 9 | 12 | 185,302 | 283,049 |
| 2010-09-01 | 0.875 | 14 | 16 | 223,305 | 366,914 |
| 2010-06-01 | 0.7826 | 18 | 23 | 220,244 | 362,406 |
| 2010-03-01 | 1.4918 | 91 | 61 | 454,974 | 274,756 |
| 2009-12-01 | 0.6667 | 8 | 12 | 24,793 | 47,916 |
| 2009-09-01 | 0.7857 | 22 | 28 | 116,420 | 201,139 |
| 2009-06-01 | 1.0 | 10 | 10 | 19,718 | 47,406 |
| 2009-03-01 | 2.3125 | 74 | 32 | 339,129 | 14,118 |
| 2008-12-01 | 2.75 | 11 | 4 | 68,554 | 17,424 |
| 2008-09-01 | 0.8077 | 21 | 26 | 137,388 | 229,987 |
| 2008-03-01 | 0.8977 | 79 | 88 | 321,518 | 98,794 |
| 2007-12-01 | 0.6667 | 8 | 12 | 66,199 | 128,992 |
| 2007-09-01 | 0.7391 | 17 | 23 | 47,159 | 84,078 |
| 2007-06-01 | 1.0909 | 12 | 11 | 28,870 | 36,421 |
| 2007-03-01 | 1.617 | 76 | 47 | 340,413 | 212,926 |
| 2006-12-01 | 2.3333 | 7 | 3 | 6,990 | 6,450 |
| 2006-09-01 | 0.3 | 9 | 30 | 21,081 | 105,678 |
| 2006-06-01 | 3.5 | 7 | 2 | 8,955 | 8,400 |
| 2006-03-01 | 2.52 | 63 | 25 | 167,223 | 91,151 |
| 2005-12-01 | 1.0667 | 16 | 15 | 42,075 | 60,962 |
| 2005-09-01 | 0.625 | 15 | 24 | 41,270 | 86,587 |
| 2005-06-01 | 1.6667 | 25 | 15 | 79,016 | 86,420 |
| 2005-03-01 | 5.1667 | 31 | 6 | 156,127 | 18,206 |
| 2004-12-01 | 0.9286 | 13 | 14 | 10,626 | 22,341 |
| 2004-09-01 | 3.6667 | 11 | 3 | 20,402 | 6,415 |
| 2004-06-01 | 1.8 | 9 | 5 | 26,300 | 16,000 |
| 2004-03-01 | 1.28 | 32 | 25 | 167,602 | 79,262 |
| 2003-12-01 | 0.9286 | 26 | 28 | 55,491 | 80,433 |
| 2003-09-01 | 14.0 | 14 | 1 | 118,272 | 3,500 |
| 2003-06-01 | 1.0 | 5 | 5 | 20,000 | 74,300 |
IDEXX Laboratories Notable Stakeholders
An IDEXX Laboratories stakeholder refers to an individual interested in an outcome of the business. Different stakeholders have different interests, and companies such as IDEXX Laboratories often face trade-offs trying to please all of them. IDEXX Laboratories' stakeholders can have a positive or negative influence on the entity's direction, and there are a lot of executives involved in getting IDEXX Laboratories' stock to the level that pleases all shareholders. Keeping track of the stakeholders is a great way to stay on top of things affecting its ongoing price.
| Jonathan Mazelsky | CEO President | Profile | |
| Jonathan Ayers | Chairman, CEO and Pres | Profile | |
| Kathy Turner | Corporate Vice President | Profile | |
| Jacqueline Studer | Corporate Vice President General Counsel, Secretary | Profile | |
| Michael Lane | Corporate Vice President General Manager | Profile | |
| Sharon Underberg | Corporate Vice President General Counsel, and Corporate Secretary | Profile | |
| Giovani Twigge | Chief Human Resource Officer, Corporate Vice President | Profile | |
| Pat Venters | Chief Marketing Officer, Vice President | Profile | |
| Brian McKeon | CFO, Principal Accounting Officer, Executive VP and Treasurer | Profile | |
| Nimrata PE | Sector Strategy | Profile | |
| Martin Smith | Executive CTO | Profile | |
| Johnny Powers | Executive VP | Profile | |
| Jay Mazelsky | Executive VP | Profile | |
| Michael Williams | Executive VP | Profile | |
| Sophie Vandebroek | Director | Profile | |
| William End | Lead Independent Director | Profile | |
| Rebecca Henderson | Independent Director | Profile | |
| Anne Szostak | Independent Director | Profile | |
| Stuart Essig | Independent Director | Profile | |
| M Szostak | Independent Director | Profile | |
| Bruce Claflin | Independent Director | Profile | |
| Sam Samad | Independent Director | Profile | |
| Barry Johnson | Independent Director | Profile | |
| Daniel Junius | Independent Director | Profile | |
| Lawrence Kingsley | Independent Director | Profile | |
| Thomas Craig | Independent Director | Profile | |
| George Fennell | Senior Officer | Profile | |
| Ken Grady | Senior Officer | Profile | |
| Jeffery Chadbourne | Director Reporting | Profile | |
| Kerry Bennett | Senior Labs | Profile | |
| Michael Johnson | Executive Officer | Profile | |
| James Polewaczyk | Executive Officer | Profile | |
| John Hart | Senior Operations | Profile |
About IDEXX Laboratories Management Performance
The success or failure of an entity such as IDEXX Laboratories often depends on how effective the management is. IDEXX Laboratories management team is responsible for propelling the future growth in the right direction and administering and controlling the business activities and accounting for the results. Ineffective management usually contributes to failure in the company's future performance for all stakeholders equally, but most importantly, for investors. So it is important to measure the effectiveness of IDEXX management before purchasing its stock. In many ways, it's all about finding the answer to one important question - Are they doing the right thing right now? How would we assess whether the IDEXX management is utilizing all available resources in the best possible way? Also, how well is the company doing relative to others in its sector and the market as a whole? The answer can be found by analyzing a few important fundamental indicators such as return on assets and return on equity.
| Last Reported | Projected for Next Year | ||
| Return On Tangible Assets | 0.30 | 0.32 | |
| Return On Capital Employed | 0.48 | 0.26 | |
| Return On Assets | 0.26 | 0.27 | |
| Return On Equity | 0.57 | 0.60 |
The data published in IDEXX Laboratories' official financial statements usually reflect IDEXX Laboratories' business processes, product offerings, services, and other fundamental events. But there are other numbers, ratios, or fundamental indicators derived from these statements that are easier to understand and visualize within the underlying realities that drive quantitative information of IDEXX Laboratories. For example, before you start analyzing numbers published by IDEXX accountants, it's critical to develop an understanding of what IDEXX Laboratories' liquidity, profitability, and earnings quality are in the context of the Health Care Equipment & Supplies space in which it operates.
Please note, the presentation of IDEXX Laboratories' financial position, as portrayed in its financial statements, is often influenced by management's estimates, judgments, and sometimes even manipulations. In the best case, IDEXX Laboratories' management is honest, while the outside auditors are strict and uncompromising. Whatever the case, the imprecision that can be found in IDEXX Laboratories' accounting process means that the reasonable investor should take a skeptical approach toward the financial statement analysis of IDEXX Laboratories. Please utilize our Beneish M Score to check the likelihood of IDEXX Laboratories' management manipulating its earnings.
IDEXX Laboratories Workforce Analysis
Traditionally, organizations such as IDEXX Laboratories use manpower efficiency calculations for various incentive schemes, employee appraisal, or as an initiative to improve the processes. However, it can also be used by investors to make long-term investment decisions. The trends in the profit per employee or revenue per employee are measured by net income or revenue divided by the current number of full-time employees over a given time interval. Because workforce needs differ across sectors, these ratios could be used to compare IDEXX Laboratories within its industry.IDEXX Laboratories Manpower Efficiency
Return on IDEXX Laboratories Manpower
| Revenue Per Employee | 332.8K | |
| Revenue Per Executive | 110.9M | |
| Net Income Per Employee | 76.8K | |
| Net Income Per Executive | 25.6M | |
| Working Capital Per Employee | 49.4K | |
| Working Capital Per Executive | 16.5M |
Check out Risk vs Return Analysis to better understand how to build diversified portfolios, which includes a position in IDEXX Laboratories. Also, note that the market value of any company could be tightly coupled with the direction of predictive economic indicators such as signals in interest. For more information on how to buy IDEXX Stock please use our How to Invest in IDEXX Laboratories guide.You can also try the Idea Optimizer module to use advanced portfolio builder with pre-computed micro ideas to build optimal portfolio .
Complementary Tools for IDEXX Stock analysis
When running IDEXX Laboratories' price analysis, check to measure IDEXX Laboratories' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy IDEXX Laboratories is operating at the current time. Most of IDEXX Laboratories' value examination focuses on studying past and present price action to predict the probability of IDEXX Laboratories' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move IDEXX Laboratories' price. Additionally, you may evaluate how the addition of IDEXX Laboratories to your portfolios can decrease your overall portfolio volatility.
| Aroon Oscillator Analyze current equity momentum using Aroon Oscillator and other momentum ratios | |
| Portfolio Diagnostics Use generated alerts and portfolio events aggregator to diagnose current holdings | |
| Cryptocurrency Center Build and monitor diversified portfolio of extremely risky digital assets and cryptocurrency | |
| Analyst Advice Analyst recommendations and target price estimates broken down by several categories | |
| Piotroski F Score Get Piotroski F Score based on the binary analysis strategy of nine different fundamentals | |
| Efficient Frontier Plot and analyze your portfolio and positions against risk-return landscape of the market. | |
| Companies Directory Evaluate performance of over 100,000 Stocks, Funds, and ETFs against different fundamentals | |
| Portfolio Comparator Compare the composition, asset allocations and performance of any two portfolios in your account |
Is IDEXX Laboratories' industry expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of IDEXX Laboratories. If investors know IDEXX will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about IDEXX Laboratories listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Quarterly Earnings Growth 0.121 | Earnings Share 10.04 | Revenue Per Share 44.073 | Quarterly Revenue Growth 0.088 | Return On Assets 0.2283 |
The market value of IDEXX Laboratories is measured differently than its book value, which is the value of IDEXX that is recorded on the company's balance sheet. Investors also form their own opinion of IDEXX Laboratories' value that differs from its market value or its book value, called intrinsic value, which is IDEXX Laboratories' true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because IDEXX Laboratories' market value can be influenced by many factors that don't directly affect IDEXX Laboratories' underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between IDEXX Laboratories' value and its price as these two are different measures arrived at by different means. Investors typically determine if IDEXX Laboratories is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, IDEXX Laboratories' price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.